Related content

Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy

By  

Current Pharmacogenomics, Vol. 4, Iss. 1, 2006-03 ,pp. : 57-67

Bentham Science Publishers

Access to resources Recommend Favorite

The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer

By Afzal Shoaib   Gusella Milena   Jensen Søren Astrup   Vainer Ben   Vogel Ulla   Andersen Jon Trærup   Brødbæk Kasper   Petersen Morten   Jimenez-Solem Espen   Adleff Vilmos   Budai Barna   Hitre Erika   Láng István   Orosz Enikő   Bertolaso Laura   Barile Carmen   Padrini Roberto   Kralovánszky Judit   Pasini Felice   Poulsen Henrik Enghusen  

Pharmacogenomics, Vol. 12, Iss. 9, 2011-09 ,pp. : 1257-1267

Future Medicine

Access to resources Recommend Favorite

Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer

By Etienne-Grimaldi Marie-Christine   Francoual Mireille   Formento Jean-Louis   Milano Géérard  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1561-1566

Future Medicine

Access to resources Recommend Favorite

Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

By Patel Hitendra   Stoller Ronald   Auber Miklos   Potter Douglas   Cai Chao   Zamboni William   Kiefer Gauri   Matin Khalid   Schmotzer Amy   Ramanathan Ramesh  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 359-363

Springer Publishing Company

Access to resources Recommend Favorite

Biweekly fluorouracil-based regimen in gastric cancer

By  

Inpharma, Vol. 1, Iss. 1426, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite